trending Market Intelligence /marketintelligence/en/news-insights/trending/HzbIrBeaNDhO9T9Vfgc0gg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Therapix Biosciences terminates acquisition by FSD Pharma

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates


Therapix Biosciences terminates acquisition by FSD Pharma

Therapix Biosciences Ltd. said it will terminate its previously signed binding letter of intent to be acquired by Ontario-based cannabis company FSD Pharma Inc.

Tel Aviv-based Therapix Biosciences said FSD Pharma proposed to modify the terms of the transaction as established by the original agreement.

Therapix said its board could not agree to revised terms and therefore decided to cancel the agreement, which will terminate Dec. 26.

Under the original letter of intent, FSD Pharma agreed to buy Therapix for $48 million in FSD stock, representing close to 10% of the company's equity.